ABOUT US
Cytiva provides the expertise and tools spanning a wide range of applications from basic research of proteins and cells to large-scale purification of biopharmaceuticals. Within the bioprocessing space, Cytiva provides products and expertise for developers and manufacturers of biotherapeutics to enable efficient, flexible and cost-effective approaches to characterization, expression and purification of biomolecules. The company offers tools and support to take recombinant proteins, monoclonal antibodies, plasma proteins, oligonucleotides and vaccines from research, through process development, to full-scale manufacturing. Cytiva has a "healthymagination" vision for the future to improve quality, decrease costs and increase access to better healthcare around the world.
Bioprocessing: cell culture, chromatography and filtration solutions, and analytics
Cytiva's portfolio encompasses both upstream and downstream processing and includes solutions for large-scale production as well as tools for process development, Quality by Design, analytical analysis and flexible manufacturing. Some key product areas are listed below:
- ReadyToProcess™ - a platform of ready to use, and single use, flexible-manufacturing equipment, includes WAVE Bioreactor™ systems and Cellbag™ single-use cell culture bioreactors.
- Xcellerex™ - a single-use technologies platform including XDR bioreactors, XDM Quad Mixers, and related single-use assemblies
- PreDictor™ 96-well plates and PreDictor RoboColumn™ units for process development of chromatography separations
- ULTA™ filters for sterile filtration and clarification applications
- MabSelect SuRe™ LX, the Capto™ media family; and Capto ImpRes all modern BioProcess™ media for all phases of purification
- ÄKTA™ systems for all scales of chromatography and filtration
- AxiChrom™ chromatography columns
- Technical support, and training through Fast Trak services
Cytiva's products enable improvements in process efficiency through optimized performance, advanced automation, integrated unit operations, and technical support. These solutions allow agile manufacturing with shortened development times and excellent facility utilization. The company offers complete start-to-finish solutions in a range of areas such as monoclonal antibodies, plasma proteins, oligonucleotides and vaccines, and is continuously developing its range of products and services.
Additionally, Cytiva has a range of products for characterization and analysis of biomolecular interactions and biomolecule stability, including Biacore™ SPR and MicroCal™ DSC systems.
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED PRODUCTS
FEATURED ARTICLES
- Manufacturing Challenges With High Concentration Biologics
- High-Concentration Drug Manufacturing Challenges And Opportunities
- Sterilizing Grade Filter Performance With Biologic Drugs
- A Closed And Automated Solution For Cell Therapy Manufacturing
- The Cure For The Cure
- A New Reality In Life Sciences
- Big Risks Yield Great Rewards In Cell Therapy
- Finding The Talent To Fuel Biopharma Breakthroughs
- Consolidating The Supply Chain For mRNA
- Getting Genomic Medicines Ready For Prime Time
- What’s Next For Computational Biology In Biotech?
- Integrating Science And Computational Talent
- Where Computation Beats Science, And Vice Versa
- The Marriage Of Wet Labs And Computational Biology
- Tech Infrastructure: What It Takes To DYI Or Outsource Computational Biology
- The Data Dilemma: How Much, And What Quality Drives AI Outcomes In Biotech?
- Managing The Hype: How Long Does It Take To Change The World?
- How Far We’ve Come: AI, ML Applications In Practice
- Meet Our Guests: EVQLV’s Andrew Satz And Recursion’s Tina Larson
- Art Of The Pivot With Elevation Oncology's Joe Ferra
- Biotech Down Under with BiomeBank's Dr. Sam Costello
- Getting CMC Right For Emerging Technologies
- IL-2 Program Profits With Bonum's Drs. John Mulligan And Neela Patel
- Following The Science To Develop Best-In-Class Cancer Drugs
- A Lean, Agile Business Model To Deliver High-Quality Oncologic Treatments
- A Tale Of Two Brothers: The Abpro Founders
- Public Sector Forged, Private Sector Tested With Renovaro BioSciences' Mark Dybul, M.D.
- Welcoming The “Era Of ADCs”
- mRNA Vaccine Platforms With Combined Therapeutics' Dr. Romain Micol
- Biotech Dealmaking with Regeneron's Nouhad Husseini
- Bioreactor Scaling Made Simpler
- Backpacks And Biotech With Luke Timmerman
- RNA Delivery Business with Liberate's Shawn Davis, Ph.D. & Walter Strapps, Ph.D.
- In Silico Approaches Towards Automated Biomanufacturing
- Bioprocessing 4.0: Digital Transformation Of Process Development
- Simulation Gets Therapies To Patients Faster And Smarter
- The Legend Steve Gorlin's Golden Rules
- CDMO + Emerging Bio Partnership With Forge's John Maslowski And Ray's Jenny Holt
- Clinical Leadership with Cue Biopharma's Anish Suri, Ph.D. & Dan Passeri, J.D.
- In Silico Optimization Of A Multimodal Chromatography mAb Polishing Step
- Bio Career Moves With Codagenix's Johanna Kaufmann, Ph.D.
- Veteran Advice From The C-Suite With Citius' Leonard Mazur
- Developing A HIC Polishing Step For The Removal Of mAb Aggregates
- Don't Be A D**k With Ochre Bio's Dr. Quin Wills
- Pragmatic Computational Biology with Andrew Satz
- Commercial Readiness with Orca Bio's Dan Kirby
- Continuous Processing For Enhanced Monoclonal Antibody Production
- Bio & The Business Of Aging with Life Biosciences' Jerry McLaughlin
- Biopharma Manufacturing For Advanced Therapies: A Panel Discussion
- Enhancing Security Of Supply Of Cell Culture Media With Single-Use Bags
- 08.29.23 -- Affinity Chromatography For mAbs, Mechanistic Modeling, And Polishing
- Sterile Filtration And Quality Risk Management
- Fiscal Turnarounds With Protalix's Eyal Rubin
- Building LEO Pharma's U.S. Presence with Brian Hilberdink
- Managing Momentum With Rezolute Bio's Nevan Charles Elam, JD
- Facing NASH Therapeutic Skepticism With 89bio's Rohan Palekar
- Introducing New Technology To A Multi-Specific Antibody Line
- Challenges To Developing High Concentration Formulation For Multi-Specific Antibodies
- Legal & Compliance Impact On Speed In The Antibody Market
- PAT In Multi-Specific Antibody Manufacturing
- Purification Strategies For New Classes Of Antibodies
- Maintaining Downstream Quality In Multi-Specific Antibody Manufacturing
- Maintaining mAb Viability After The Exponential Growth Phase
- Multi-Specific Antibody Development: What Challenges The Need For Speed?
- Biotech Cash Management With Allan Shaw
- Outsourcing: Biomanufacturers May Need Consultants More Than Ever
- Establishing Research With Horizon Therapeutics' Robert Stoffel, Ph.D.
- Surviving The Microbiome Market with MaaT Pharma's Hervé Affagard
- The Colloidal Particle Adsorption (CPA) Model In IEX
- COO Liftoff With Rocket Pharmaceuticals' Kinnari Patel, PharmD
- Alkaline Stability Of Modern Protein A Chromatography Resins
- Protein L Affinity Resin Is Ready To Move To Manufacturing
- Improving Efficiency In Upstream Process Development
- ML-Enabled Drug Discovery With LabGenius' James Field, Ph.D.
- Biopharma Comebacks With Vincerx's Ahmed Hamdy, MD
- Origins Of A Biopharma VC Deal With Bernat Olle, Ph.D. And Parag Shah
- Population-Level Health Impact With Vaxxinity's John Krayacich
- The Face Of African Biotech with Adrienne Leussa, Ph.D.
- The Innovation Reduction Act With Allan Shaw
- Propagating Peptides With Peptilogics' Jonathan Steckbeck, Ph.D.
- Applying Pandemic Learnings To Future State Manufacturing
- Building Biopharma Supply Chain Resilience, Cost Reduction
- Where Has The Best Progress Toward Pandemic Response Happened?
- Biomanufacturing Anywhere To Meet Demand, + Regulatory Concerns
- mRNA’s Impact On Cost And Capacity To Surge Biopharma Production
- The Roles Of Automation And Monitoring In Surge Manufacturing
- Hiring Up For Surge Manufacturing Capacity
- Post-COVID Surge Manufacturing Progress
- Meet Dr. Zoltán Kis And The Wellcome Leap RNA R3 Program
- Get Acquainted With Kayla Hannon And Surge Manufacturing
- Resilient Biopharma Leadership With Ambrx's Dan O'Connor
- Funding A Neurodegeneration Startup With Coya Therapeutics' Howard Berman
- A More NIIMBL Biotech Workforce With John Balchunas
- A More NIIMBL Biotech Workforce With John Balchunas
- AAV Full/Empty Capsid Separation Using Mechanistic Modeling
- Recombinant Protein Purification Optimization With HIC
- Alkaline Stability Of Fc And VH3 Binding In Protein A Resins
- How To Develop An Efficient Downstream Purification Process For bsAbs
- Building Flagship Pioneering With Avak Kahvejian, Ph.D.
- Thinking Differently About The Future Of mRNA Manufacturing
- “Continuous Improvement:” Defining Your Purification Process & Product Specifications
- Considerations To Better Understand/Mitigate Raw Material Variability
- Is The IVT Reaction A Coy Mistress? The Knowns & Unknowns
- The Current State Of The mRNA Supply-Chain — In Brief
- How To Foster Greater R&D And CMC Integration In Your Organization
- Assessing The Manufacturability Of Prospective Lead mRNA Candidates
- Therapeutic Molecules From Moss with eleva's Andreas Schaaf And Björn Cochlovius, Ph.D.
- Gene Tx For Hearing Loss With Sensorion's Nawal Ouzren
- How To Best Optimize mRNA Production Workflows
- Controlling Trace Impurities In Chemically Defined Media
- Approvals & Mergers: Inside Enzyvant With Bill Symonds, Pharm.D.
- Functional Ectopic Organs with LyGenesis' Michael Hufford, Ph.D.
- Next-Gen Nanobodies With MoonLake's Jorge Santos Da Silva, Ph.D.
- Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
- TCRs In Personalized Oncology With BlueSphere Bio's Keir LoIacono
- BoB@JPM: Self-Replicating RNA With Elixirgen's Akihiro Ko
- BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D.
- BoB@JPM: Gene Writing With Tessera's Michael Severino, M.D.
- Challenges Of The IVT Reaction In mRNA Production
- How To Maintain A Nuclease Free Environment During mRNA Production
- How To Choose A Capping Method In MRNA Production
- BoB@JPM: Post-IPO With Bolt Biotherapeutics' Drs. Randall Schatzman and Edith Perez
- Simplifying Bioprocess Data Collection
- Key Components And Functions Of The ÄKTA oligosynt™ Synthesizer
- Small-Scale Oligonucleotide Synthesizer That Supports Scale Up
- LNP Formulation For mRNA delivery
- mRNA Product Purification Process Strategies
- mRNA Product IVT Process Insights
- mRNA: Challenges And Strategies Related To The DNA Template Process
- Introduction To mRNA Manufacturing
- BoB@JPM: Academia To Industry With Oncolytics' Matt Coffey, Ph.D.
- A Guide To Polishing Chromatography In Process Development
- BoB@JPM: Support Of A Blossoming Pipeline With Sangamo's Sandy Macrae, Ph.D.
- Using Mathematical Models To Improve Process Development
- Building A Better COVID Vaccine With Ocugen's Shankar Musunuri, Ph.D.
- Understanding The Oligonucleotide Synthesis Process
- Biopharma Resilience: Addressing Manufacturing And Talent Needs
- Biopharma Resilience: Building Biomanufacturing Capacity
- Modality-Agnostic Drug Discovery With Cullinan Oncology's Nadim Ahmed
- How Distributed Automation And DPM Support Resilient Biomanufacturing
- Women In Biotech With Bill & Melinda Gates MRI's Piper Trelstad, Ph.D.
- rAAV Production Using HEK293 Cell Line And Transfection Medium
- Establishing A Robust Workflow To Identify High-Performing Clones
- Computational Drug Discovery With Gain Therapeutics' Matthias Alder
- Dissecting Spesolimab's Approval With Boehringer Ingelheim's Carine Boustany
- AI & Computational Biology With Recursion's Chris Gibson, Ph.D.
- Financing Biopharma Innovation With Allan Shaw
- Gene Therapy For Chronic Inflammation With Xalud's Howard Rutman, M.D.
- Pursuing A “Biologic Revolution” With Vaxxinity’s Mei Mei Hu
- The Antibody Engine With Abpro's Chan Brothers